© 2024 TORL BioTherapeutics, LLC.
All rights reserved.

Advancing novel
antibody-based therapies to
transform lives of cancer patients.

Learn More

Our Mission

TORL BioTherapeutics is building a preeminent biopharmaceutical company dedicated to the discovery, development, and commercialization of antibody-based therapies to improve and extend the lives of people with cancer worldwide.

TORL is developing new antibody-based therapies, both monoclonal (mABs) and drug conjugates (ADCs), for novel cancer targets identified through an exclusive strategic partnership with the world-renowned Slamon Research Lab at the University of California, Los Angeles (UCLA).

Our Approach

Leveraging a one-of-a-kind research partnership and an experienced team to advance a multitarget antibody-based pipeline through global clinical development

Robust Pipeline of Targeted Antibody-based Therapies

  • Multiple active programs in the clinic globally spanning antibody modalities focused on large, addressable markets with serious unmet medical need
  • All programs target a molecular or genetic signature coupled with companion diagnostic to ensure the right drug is getting to the right patient

Experience in Global Clinical Development and Beyond

  • Highly accomplished founders and executive team with experience discovering, developing and commercializing high impact medicines in solid tumors and blood cancers
  • Collaborations with expert clinicians and strategic partnerships with global clinical research networks ensure a streamlined path to bring investigational medicines to patients in need

Our Team

Our executive team has deep experience discovering, developing and commercializing some of the most impactful medicines for people living with cancer.

Board Members
Management Team

Discovery & Development Pipeline

Our clinical pipeline includes multiple targets with a molecular or genetic signature in indications with serious unmet medical need

Target Therapeutic (Modality) Pre-Clinical Phase 1 Phase 2
CLDN6
TORL-1-23 (ADC)
CLDN18.2
TORL-2-307-ADC (ADC)
CDH17
TORL3600-001 (ADC)
DLK1
TORL4-500-001
(ADC)

News & Publications

TORL BioTherapeutics, LLC
09/15/24

TORL BioTherapeutics Presents Updated Phase 1 Results of Novel Claudin 6 Targeted Antibody-Drug Conjugate TORL-1-23 at the 2024 European Society of Medical Oncology Congress

LOS ANGELES, Sept. 15, 2024 /PRNewswire/ — TORL BioTherapeutics, LLC (“TORL Bio” or “the Company”), a clinical stage biotechnology company discovering and developing new antibody-based immunotherapies to improve and extend the lives of patients with cancer worldwide, today announced the presentation of additional results from the ongoing Phase 1 study of TORL-1-23, the Company’s Claudin 6 (CLDN6) targeted antibody-drug conjugate (ADC) in patients with advanced cancer at the 2024 European Society of Medical Oncology Congress (ESMO 2024) in Barcelona, Spain.
TORL Biotherapeutics, LLC
04/10/24

TORL Biotherapeutics Announces $158 Million Oversubscribed Series B-2 Financing to Advance the Clinical Development of its Novel Antibody-Drug Conjugate (ADC) Oncology Pipeline

TORL BioTherapeutics, LLC (TORL), is a clinical-stage biotechnology company involved in discovery and development of new antibody-based immunotherapies designed to improve and extend the lives of patients with cancer worldwide. Today, the Company announced its closing of an oversubscribed $158 million Series B-2 financing. The financing led by Deep Track Capital, with new participation from leading global biotechnology investors including RA Capital Management, Perceptive Advisors, and Avidity Partners as well as all existing biotechnology investors including Goldman Sachs Alternatives, UC Investments, Bristol Myers Squibb, Vertex Ventures HC, Moore Strategic Ventures, Blue Owl Healthcare Opportunities, and Perceptive Xontogeny Venture Fund, brings the total raised to date to greater than $350 million. Proceeds from this Series B-2 financing will be used to continue the clinical development of TORL-1-23, the Company’s first-in-class ADC to treat CLDN 6+ tumors, through Phase 1 and a pivotal Phase 2 trial that will start in the second half of 2024. This Phase 2 trial is designed to facilitate regulatory review and potential approvals for TORL-1-23 as a new therapy for patients with CLDN 6+, platinum-resistant ovarian cancer. Proceeds will also be used to fund the on-going Phase 1 studies for the TORL-2-307 program, both a monoclonal antibody (mAb) and an ADC, for the treatment of CLDN 18.2+ solid tumors, TORL-3-600, an ADC for the treatment of CDH17+ colorectal cancer, and TORL-4-500, an ADC for the treatment of Delta like non-canonical Notch Ligand 1 (DLK1) positive solid tumors.
TORL Biotherapeutics, LLC
01/09/24

TORL Biotherapeutics Announces Appointment of Mark J. Alles as Chairman and Chief Executive Officer; Highlights Significant Progress of its Oncology Clinical Programs

Mark Alles, Executive Chairman of TORL BioTherapeutics, LLC (TORL) and former Chairman and CEO of Celgene Corporation has been appointed TORL’s Chairman and CEO. Mark brings more than 35 years of global biopharmaceutical experience, and will lead TORL as it advances its expanding clinical-stage antibody programs in oncology and builds additional programs through the high-value discovery pipeline established and led by TORL Scientific Founder Dennis Slamon, M.D., Ph.D.
TORL BioTherapeutics, LLC
06/01/23

TORL BioTherapeutics Announces Initial Results of Novel Claudin 6 (CLDN6) Targeted Antibody Drug Conjugate (ADC) TORL-1-23 Selected for Presentation at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting

LOS ANGELES, June 1, 2023 /PRNewswire/ — TORL BioTherapeutics LLC (“TORL Bio” or “the Company”) announces the initial results from an ongoing phase I study of their claudin 6 (CLDN6) targeted antibody drug conjugate (ADC), TORL-1-23, in patients with advanced cancer on the American Society of Oncology (ASCO) website